BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Strs Ohio

Strs Ohio raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 30.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,000 shares of the company’s stock after purchasing an additional 2,100 shares during the period. Strs Ohio’s holdings in BridgeBio Pharma were worth $363,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Arizona State Retirement System raised its position in shares of BridgeBio Pharma by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 25,134 shares of the company’s stock valued at $663,000 after purchasing an additional 386 shares in the last quarter. Diversified Trust Co raised its position in shares of BridgeBio Pharma by 2.5% in the 3rd quarter. Diversified Trust Co now owns 17,111 shares of the company’s stock valued at $451,000 after purchasing an additional 411 shares in the last quarter. Amalgamated Bank raised its position in shares of BridgeBio Pharma by 3.8% in the 3rd quarter. Amalgamated Bank now owns 15,775 shares of the company’s stock valued at $416,000 after purchasing an additional 576 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of BridgeBio Pharma by 4.9% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,289 shares of the company’s stock valued at $403,000 after purchasing an additional 720 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of BridgeBio Pharma by 1.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 65,773 shares of the company’s stock valued at $2,655,000 after purchasing an additional 904 shares in the last quarter. 99.85% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Price Performance

Shares of BBIO opened at $24.88 on Monday. The company has a market cap of $4.37 billion, a P/E ratio of -6.31 and a beta of 1.03. The stock has a fifty day moving average price of $29.42 and a 200 day moving average price of $31.79. BridgeBio Pharma, Inc. has a 12 month low of $12.75 and a 12 month high of $44.32.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.09). The company had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $4.78 million. BridgeBio Pharma’s revenue was down 8.4% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.92) EPS. As a group, research analysts anticipate that BridgeBio Pharma, Inc. will post -3.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BBIO shares. JPMorgan Chase & Co. upped their target price on BridgeBio Pharma from $35.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Citigroup boosted their price target on BridgeBio Pharma from $42.00 to $46.00 and gave the company a “buy” rating in a report on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and issued a $47.00 price target on shares of BridgeBio Pharma in a report on Monday, March 4th. BMO Capital Markets assumed coverage on BridgeBio Pharma in a report on Wednesday, January 31st. They issued a “market perform” rating and a $37.00 price target for the company. Finally, Raymond James assumed coverage on BridgeBio Pharma in a report on Thursday, March 21st. They issued an “outperform” rating and a $45.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average price target of $47.82.

Insider Transactions at BridgeBio Pharma

In other news, Director Randal W. Scott sold 2,500 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $34.00, for a total value of $85,000.00. Following the completion of the transaction, the director now owns 6,500 shares of the company’s stock, valued at $221,000. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 28.52% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.